Alectinib Approved as an Adjuvant Treatment for Lung Cancer - Cancer Currents Blog

National Cancer Institute sent this bulletin at 05/08/2024 12:45 PM EDT

Having trouble viewing this email? View it as a Web page.

Alectinib Approved as an Adjuvant Treatment for Lung Cancer
05/08/2024
	FDA has approved alectinib (Alecensa) as adjuvant therapy for people with lung cancer who have ALK-positive tumors. In a clinical trial, alectinib helped people live longer after surgery without their cancer returning than chemotherapy.

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.